Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Double-blind Study to Evaluate the Efficacy and Safety of Dexlansoprazole (30 mg QD) Compared to Placebo on Heartburn Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD)

NCT02873689 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT02873689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02873689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Double-blind Study to Evaluate the Efficacy and Safety of Dexlansoprazole (30 mg QD) Compared to Placebo on Heartburn Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD)
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
December 27, 2016
Completion date
April 19, 2018
Enrollment
217 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal reflux disease, heartburn